SCHEMBL5150143

SCHEMBL5150143

N#CC(=O)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.66
CES1 P23141 1/20 0.66
TP53 P04637 1/20 0.64
ALDH1A1 P00352 6/20 0.62
TSHR P16473 3/20 0.62
KMT2A Q03164 6/20 0.61
MAPT P10636 6/20 0.61
MEN1 O00255 5/20 0.61
HTT P42858 4/20 0.61
HSP90AA1 P07900 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
MITF O75030 1/20 0.61
PRSS1 P07477 1/20 0.54
PRSS2 P07478 1/20 0.54
PRSS3 P35030 1/20 0.54
S1PR2 O95136 1/20 0.54
OPRK1 P41145 1/20 0.54
LMNA P02545 1/20 0.53
RXFP1 Q9HBX9 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29128742 0.83 CES2 (0.66) CES2CES1TP53ALDH1A1TSHR
SCHEMBL30725444 0.83 CES2 (0.66) CES2CES1TP53ALDH1A1TSHR
SCHEMBL8026060 0.82 CES2 (0.56) CES2CES1TP53ALDH1A1TSHR
SCHEMBL8026063 0.82 CES2 (0.56) CES2CES1TP53ALDH1A1TSHR
SCHEMBL10925104 0.82 CYP3A4 (0.57) CES2CES1TP53ALDH1A1TSHR
SCHEMBL31388927 0.81 CES2 (0.59) CES2CES1TP53ALDH1A1TSHR
Water SCHEMBL28303785 0.80 TP53 (0.96) CES2CES1TP53ALDH1A1TSHR
SCHEMBL6607552 0.80 ALDH1A1 (0.67) CES2CES1TP53ALDH1A1TSHR
SCHEMBL31374765 0.80 CES1 (1.00) CES2CES1TP53ALDH1A1TSHR
SCHEMBL181572 0.80 CES2 (0.78) CES2CES1TP53ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451162-A4 SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION RIGEL PHARMACEUTICALS INC (US) 2007-02-07 EP disclosed
US-7153880-B2 Substituted diphenyl heterocycles useful for treating HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2006-12-26 US disclosed
US-7115642-B2 Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20040266840-A1 Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection MIDCAP FINANCIAL TRUST 2004-12-30 US disclosed
US-20040236112-A1 Substituted diphenyl heterocycles useful for treating HCV infection MIDCAP FINANCIAL TRUST 2004-11-25 US disclosed
WO-2004099164-A1 SUBSTITUTED DIPHENYL ISOXAZOLES, PYRAZOLES AND OXADIAZOLES USEFUL FOR TREATING HCV INFECTION RIGEL PHARMACEUTICALS, INC. (US) 2004-11-18 WO disclosed
EP-1451162-A1 SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION Rigel Pharmaceuticals, Inc. (US) 2004-09-01 EP disclosed
US-6759538-B2 PREVENTION INFECTIONS OF HEPATITIS C VIRUS RIGEL PHARMACEUTICALS, INC. 2004-07-06 US disclosed
US-20030165561-A1 Substituted diphenyl heterocycles useful for treating HCV infection MIDCAP FINANCIAL TRUST 2003-09-04 US disclosed
WO-2003040112-A1 SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION RIGEL PHARMACEUTICALS, INC. (US) 2003-05-15 WO disclosed
US-4228082-A FUNGICIDES OR CHEMICAL INTERMIDIATES FOR 1,2,4-TRIAZINONE HERBICIDES DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1980-10-14 US disclosed
US-4224226-A FUNGICIDES BY CONDENSING AN ACYL CYANIDE WITH EITHER A TERTIARY ALCOHOL OR AN ALKENE DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1980-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266840-A1 Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection HAVCR2, MAVS, RPL35 CES2 2713/4885CES1 774/4885TP53 1208/4885
US-20040236112-A1 Substituted diphenyl heterocycles useful for treating HCV infection HAVCR2, HCCS, PCNA CES2 1333/4885CES1 1082/4885TP53 383/4885
US-20030165561-A1 Substituted diphenyl heterocycles useful for treating HCV infection HAVCR2, HCCS, PCNA CES2 1333/4885CES1 1082/4885TP53 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.